FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation

BACKGROUND: The majority of breast cancers (BCs) expressing estrogen receptor (ER) have shown endocrine resistance. Our previous study demonstrated that ferredoxin reductase (FDXR) promoted mitochondrial function and ER+ breast tumorigenesis. But the underlying mechanism is not clear. METHODS: Liqui...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Chaojun, Gao, Ronghui, Gao, Chuan, Hong, Kai, Cheng, Meng, Liu, Xiaojing, Zhang, Qing, Zhang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189134/
https://www.ncbi.nlm.nih.gov/pubmed/37207154
http://dx.doi.org/10.3389/fonc.2023.1105117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189134/
https://www.ncbi.nlm.nih.gov/pubmed/37207154
http://dx.doi.org/10.3389/fonc.2023.1105117

Ejemplares similares